Vanguard Group
BIAF icon

Vanguard Group’s bioAffinity Technologies BIAF Stock Holding History

Vanguard Group’s Portfolio BIAF Stock Details BIAF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-10,429
Closed -$30.9K – 4341
2025
Q3 		$30.9K Buy
10,429
+9,074
+670% +$72.2K ﹤0.01% 4324
2025
Q2 		$11.7K Sell
1,355
-4,542
-77% -$51.9K ﹤0.01% 4261
2025
Q1 		$46K Sell
5,897
-2,799
-32% -$51.3K ﹤0.01% 4196
2024
Q4 		$244K Hold
8,696
– – ﹤0.01% 4071
2024
Q3 		$543K Buy
8,696
+2,963
+52% +$178K ﹤0.01% 3953
2024
Q2 		$372K Buy
5,733
+3,389
+145% +$235K ﹤0.01% 4070
2024
Q1 		$142K Buy
2,344
+1,677
+251% +$87.5K ﹤0.01% 4212
2023
Q4 		$29.4K Hold
667
– – ﹤0.01% 4418
2023
Q3 		$23.3K Buy
+667
New +$33.9K ﹤0.01% 4485

Other funds holding BIAF

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group's BIAF Position: Q4 2025 in Review

Vanguard Group sold out of bioAffinity Technologies (BIAF) in Q4 2025, closing a stake of 10,429 shares — an estimated $30.9K sold.

Vanguard Group first reported a position in BIAF in Q3 2023 and held it in 9 quarters. The position peaked at $543K in Q3 2024. 9 funds tracked by Wall St. Rank hold BIAF as of Q4 2025.

  • Vanguard Group reported no remaining bioAffinity Technologies position as of Q4 2025 after selling out during the quarter.
  • Vanguard Group sold 10,429 bioAffinity Technologies shares in Q4 2025, an estimated $30.9K.
  • Vanguard Group first reported a position in bioAffinity Technologies in Q3 2023 and held it in 9 quarters.
  • Vanguard Group's bioAffinity Technologies position peaked at $543K in Q3 2024.
  • 9 funds tracked by Wall St. Rank held bioAffinity Technologies as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.